Last edition
News about "Type 2 diabetes treatment"
Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes
Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.
Type 2 Diabetes Treatment | 08/06/2026 | By News Bureau
Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing
Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.
Type 2 Diabetes Treatment | 08/06/2026 | By News Bureau
Alkem Brings Semaglutide Pre-Filled Syringes to Indian Market
Alkem has launched semaglutide pre-filled syringes in India, introducing a convenient single-shot administration option for the management of Type 2 Diabetes (T2D) and obesity.
Type 2 Diabetes Treatment | 03/06/2026 | By News Bureau
Dr. Reddy's Launches Oral Semaglutide Biosimilar Obeda Tablets in India
Dr. Reddy's launches Obeda oral semaglutide tablets in India, strengthening its GLP-1 portfolio after recent generic semaglutide injection launches in India and Canada for diabetes and obesity care.
Type 2 Diabetes Treatment | 20/05/2026 | By News Bureau | 168
Dr. Reddy's Laboratories Wins Health Canada Nod for Generic Semaglutide Injection
Dr. Reddy's Laboratories secures Health Canada approval for generic semaglutide injection, becoming the first to gain market authorisation in Canada ahead of the review timeline.
Type 2 Diabetes Treatment | 29/04/2026 | By News Bureau | 136
Lupin Launches Diabetes Drug Combination in the US
Lupin launches dapagliflozin and metformin extended-release tablets in the US, offering a bioequivalent and cost-effective alternative for type 2 diabetes management.
Type 2 Diabetes Treatment | 22/04/2026 | By News Bureau | 129
Inventia Healthcare Launches Generic Dapagliflozin in US After FDA Approval
Inventia Healthcare has secured FDA approval for dapagliflozin tablets and begun Day-One commercialisation, expanding access to affordable diabetes and heart failure treatment in the US.
Type 2 Diabetes Treatment | 09/04/2026 | By News Bureau | 310
Endogenex Raises USD 50 Million to Advance Novel Diabetes Treatment
Series C extension led by Arboretum Ventures to fund pivotal clinical study and support regulatory pathway for ReCET System.
Type 2 Diabetes Treatment | 26/03/2026 | By News Bureau | 184
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy